Compound repurposing
Small molecule compounds are being studied for repurposing in COVID-19 treament and research. Multiple small molecules that are approved to treat other disorders have shown potential effects on key proteins involved in SARS-CoV-2 host cell entry and replication. Repurposing of existing compounds is advantageous for speed - reducing timescales compared to conventional drug discovery. Researchers can save up to 50% on these small molecules for COVID-19 research, as they are up to half the price of other suppliers.
(+)-Bicuculline (HB0896)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methiodide (HB0893)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methobromide (HB0894)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
(-)-Bicuculline methochloride (HB0895)
Description:Prototypic, competitive GABAA receptor antagonist
Purity:>98%
Haloperidol hydrochloride (HB1842)
Description:Dopamine receptor antagonist with partial D2-like selectivity
Purity:>99%
Mifepristone (HB2783)
Description:Potent glucocorticoid and progesterone receptor antagonist. Also used for gene editing as a mifepristone inducible Cas9 and Cpf1 CRISPR effector.
Purity:>99%
(+)-MK 801 maleate (HB0004)
Description:Potent, selective, non-competitive NMDA receptor antagonist
Purity:>98%
MPEP hydrochloride (HB0426)
Description:Potent, selective mGluR5 antagonist / mGluR4 positive allosteric modulator
Purity:>98%
Tamoxifen (HB0601)
Description:Estrogen receptor antagonist/ partial agonist. May be used in genome engineering (e.g. CreER/ CRISPR-Cas9).
Purity:>99%